In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance | Synapse
April 24, 2026
In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance
Key Points
This research investigates the effectiveness of daptomycin combined with ceftaroline for treating endocarditis caused by Enterococcus faecalis, focusing on cases with and without aminoglycoside resistance.
Conducted in vitro assessments of antibiotic combinations against Enterococcus faecalis.
Evaluated in vivo efficacy using a model of endocarditis.
Compared outcomes with and without high-level aminoglycoside resistance.
The combination of daptomycin and ceftaroline demonstrates notable effectiveness against Enterococcus faecalis.
In vitro results indicate enhanced antibacterial activity compared to individual drugs.
In vivo results support the potential clinical utility of this combination therapy.
Abstract
Daptomycin plus ceftaroline represents a promising alternative for treating EFIE. Further clinical studies are needed to confirm these findings.